AGL 40.00 No Change ▼ 0.00 (0%)
AIRLINK 127.11 Increased By ▲ 0.07 (0.06%)
BOP 6.61 Decreased By ▼ -0.06 (-0.9%)
CNERGY 4.52 Increased By ▲ 0.01 (0.22%)
DCL 8.58 Increased By ▲ 0.03 (0.35%)
DFML 41.75 Increased By ▲ 0.31 (0.75%)
DGKC 87.32 Increased By ▲ 0.47 (0.54%)
FCCL 32.55 Increased By ▲ 0.27 (0.84%)
FFBL 64.99 Increased By ▲ 0.19 (0.29%)
FFL 10.33 Increased By ▲ 0.08 (0.78%)
HUBC 109.50 Decreased By ▼ -0.07 (-0.06%)
HUMNL 14.70 Increased By ▲ 0.02 (0.14%)
KEL 5.08 Increased By ▲ 0.03 (0.59%)
KOSM 7.56 Increased By ▲ 0.10 (1.34%)
MLCF 41.50 Increased By ▲ 0.12 (0.29%)
NBP 59.50 Decreased By ▼ -0.91 (-1.51%)
OGDC 192.40 Increased By ▲ 2.30 (1.21%)
PAEL 28.15 Increased By ▲ 0.32 (1.15%)
PIBTL 7.83 No Change ▼ 0.00 (0%)
PPL 151.50 Increased By ▲ 1.44 (0.96%)
PRL 26.55 Decreased By ▼ -0.33 (-1.23%)
PTC 16.12 Increased By ▲ 0.05 (0.31%)
SEARL 83.80 Decreased By ▼ -2.20 (-2.56%)
TELE 7.78 Increased By ▲ 0.07 (0.91%)
TOMCL 35.49 Increased By ▲ 0.08 (0.23%)
TPLP 8.14 Increased By ▲ 0.02 (0.25%)
TREET 16.14 Decreased By ▼ -0.27 (-1.65%)
TRG 53.15 Decreased By ▼ -0.14 (-0.26%)
UNITY 26.25 Increased By ▲ 0.09 (0.34%)
WTL 1.26 No Change ▼ 0.00 (0%)
BR100 9,991 Increased By 106.9 (1.08%)
BR30 31,161 Increased By 561.2 (1.83%)
KSE100 94,150 Increased By 795.1 (0.85%)
KSE30 29,170 Increased By 239.4 (0.83%)

Bangladesh's leading drug maker Beximco Pharmaceuticals Limited (BPL) said on Saturday it has raised 6.5 million pounds through the issue of 8,175,750 further global depository receipts (GDRs) on the London Stock Exchange, each representing one ordinary share of 10 taka each at an issue price of 80 pence per GDR.
The newly issued GDRs were admitted for trading on June 1 on the Alternative Investment Market (AIM) of the London Stock Exchange, a BPL statement said.
"We have been delighted by the interest in Beximco from international investors since the company's IPO in London last year and we are grateful to them for their continuing support in this fundraising as we develop the infrastructure of our business and invest in its growth," said Nazmul Hassan, Chief Executive Officer of Beximco Pharmaceuticals said in the statement.

Copyright Reuters, 2006

Comments

Comments are closed.